Mono Pharmacare Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Mono Pharmacare Ltd is ₹ 13.1 as of 06 May 15:30 . The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 . The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Mono Pharmacare Ltd is 0 % as of March 2023 .The Dividend Payout of Sai Parenterals Ltd is 0 % as of March 2023.

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Mono Pharmacare Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Mono Pharmacare Ltd or Sai Parenterals Ltd?

Market cap of Mono Pharmacare Ltd is 23 Cr while Market cap of Sai Parenterals Ltd is 2,244 Cr

What are the key factors driving the stock performance of Mono Pharmacare Ltd and Sai Parenterals Ltd?

The stock performance of Mono Pharmacare Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mono Pharmacare Ltd and Sai Parenterals Ltd?

As of May 6, 2026, the Mono Pharmacare Ltd stock price is INR ₹13.1. On the other hand, Sai Parenterals Ltd stock price is INR ₹508.05.

How do dividend payouts of Mono Pharmacare Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Mono Pharmacare Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.